Related Experiment Video
Updated: Sep 3, 2025
MicroRNA-based Regulation of Picornavirus Tropism
Published on: February 6, 2017
A Quality by Design Approach in Pharmaceutical Development of Non-Viral Vectors with a Focus on miRNA
Ioana Toma1, Alina Silvia Porfire1, Lucia Ruxandra Tefas1
1Department of Pharmaceutical Technology and Biopharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Abstract:
Cancer is the leading cause of death worldwide. Tumors consist of heterogeneous cell populations that have different biological properties. While conventional cancer therapy such as chemotherapy, radiotherapy, and surgery does not target cancer cells specifically, gene therapy is attracting increasing attention as an alternative capable of overcoming these limitations. With the advent of gene therapy, there is increasing interest in developing non-viral vectors for genetic material delivery in cancer therapy. Nanosystems, both organic and inorganic, are the most common non-viral vectors used in gene therapy. The most used organic vectors are polymeric and lipid-based delivery systems. These nanostructures are designed to bind and protect the genetic material, leading to high efficiency, prolonged gene expression, and low toxicity. Quality by Design (QbD) is a step-by-step approach that investigates all the factors that may affect the quality of the final product, leading to efficient pharmaceutical development. This paper aims to provide a new perspective regarding the use of the QbD approach for improving the quality of non-viral vectors for genetic material delivery and their application in cancer therapy.
Insights
This study explores using the Quality by Design (QbD) approach to enhance non-viral vectors for cancer gene therapy. QbD aims to improve the quality and effectiveness of these nanocarriers for delivering genetic material to cancer cells.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background:
- Cancer remains a leading global cause of death, with tumors comprising diverse cell populations.
- Conventional cancer treatments lack specificity, leading to significant side effects.
- Gene therapy offers a promising alternative for targeted cancer treatment, necessitating efficient delivery systems.
Purpose of the Study:
- To introduce the Quality by Design (QbD) approach for optimizing non-viral vectors in cancer gene therapy.
- To enhance the quality and efficacy of nanocarriers for genetic material delivery.
- To provide a novel perspective on QbD application in pharmaceutical development for cancer treatment.
Main Methods:
- Focus on polymeric and lipid-based nanostructures as organic non-viral vectors.
- Investigate the role of nanocarriers in binding, protecting, and delivering genetic material.
- Apply the Quality by Design (QbD) systematic approach to pharmaceutical development.
Main Results:
- Non-viral nanosystems, particularly polymeric and lipid-based ones, show potential for targeted gene delivery.
- These nanostructures can achieve high efficiency, prolonged gene expression, and reduced toxicity.
- The QbD approach offers a framework for ensuring consistent quality and performance of these vectors.
Conclusions:
- The Quality by Design (QbD) approach can significantly improve the quality of non-viral vectors for cancer gene therapy.
- Optimized non-viral vectors hold promise for more effective and safer cancer treatments.
- Further research into QbD for nanomedicine development is warranted.
